 REDWOOD CITY, Calif., Nov. 01, 2022 GLOBE NEWSWIRE -- Revolution Medicines, Inc. Nasdaq: RVMD, a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the third quarter 2022 on Monday, November 7, 2022, after market close. At 4:30 p.m. Eastern Time that day 1:30 p.m. Pacific Time, Revolution Medicines senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. 